Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma

Štrbac, Danijela; Goričar, Katja; Dolžan, Vita; Kovač, Viljem

doi:10.1515/raon-2018-0005

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matrix metalloproteinases are considered to be regulatory factors of tumour microenvironment and carcinogenesis (Strbac et al 2018). The MMPs are involved in the key ECM degradation of proteolytic enzyme family (Curran et al 2004;Chen KE et al 2018;Qiao et al 2018) and are used to disrupt the interaction of cells-cells and cells-ECM by tissue remodelling.…”

Section: Discussionmentioning

confidence: 99%

Resveratrol inhibits ACHN cells via regulation of histone acetylation

Dai

Chen

Wang

et al. 2020

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: The relationship between resveratrol and histone acetylation in renal cell carcinoma (RCC) has not yet been reported. Objective: To explore the functional role of resveratrol in RCC. Materials and methods: Functional experiments were performed to determine proliferatio n of ACHN cells with treatment of resveratrol (0, 7.8125, 15.625, 31.25 and 62.5 lg/mL, for 12, 24 and 48 h of culture) or 0.1 lM SAHA. The enzyme activities of MMP-2/-9 were measured by gelatine zymography and histone acetylation by Western blot. Results: When the cells were treated with 15.625, 31.25 and 62.5 lg/mL resveratrol, ACHN cells viability was 73.2 ± 3.5%, 61.4 ± 3.1%, 50.2 ± 4.7% for 12 h, 62.7 ± 4.5%, 52.4 ± 5.5%, 40.2 ± 3.8% for 24 h, and 60.8 ± 3.7%, 39.4 ± 5.1%, 37.6 ± 2.7% for 48 h, and the wound closure (%) of migration was increased from 0.6 to 0.7, 0.85, 0.9 for 12 h and from 0.23 to 0.3, 0.48, 0.59 for 24 h. The invasion rate was 8.5 ± 0.9%, 7.4 ± 0.3% and 5.8 ± 0.6%, and cell cycle was arrested at G1 from 42.5 ± 2.9% to 55.3 ± 5.7%, 59.8 ± 3.4%, 68.7 ± 4.6%. MMP-2/-9 expression (p < 0.05) was inhibited by resveratrol. The protein levels of histone acetylation (p < 0.01) was increased by resveratrol. Discussion and conclusions: Our results suggest that these effects might be related to a high level of histone acetylation, and resveratrol can be considered as an alternative treatment for RCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Resveratrol inhibits ACHN cells via regulation of histone acetylation

Dai

Chen

Wang

et al. 2020

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…It has been shown that apart from clinical characteristics such as C-reactive protein or tumor stage, serum and genetic markers may be associated with treatment outcome in MM [10,[18][19][20][21][22][23][24][25][26][27][28][29]. disease risk, diagnosis and treatment are also emerging [31]. Mesothelin is the only clinically validated biomarker in the diagnosis of mesothelioma.…”

Section: Biomarker Guided Chemotherapy Treatment In Malignant Mesothementioning

confidence: 99%

Current Mesothelioma Treatment and Future Perspectives

Štrbac¹,

Goričar²,

Kovač³

et al. 2020

Mesothelioma

View full text Add to dashboard Cite

The established treatments in malignant mesothelioma are based on trimodality approach including surgery, radiation and chemotherapy. Such approach has proved to clinically benefit mesothelioma patients, however the current treatments seem to have reached a limit regarding the survival and disease control. One approach to overcome the limitations of current treatments is focused on finding appropriate serum or genetic biomarkers that could support personalized medicine and improve outcomes with established treatment modalities in mesothelioma patients. The other approach is exploiting better understanding of molecular and genetic characteristics of mesothelioma to search for new treatment modalities. Immunotherapy with anti PD-1, PD-L1 and CTLA-4 agents is a new frontier in mesothelioma treatment. As in many solid tumors, CAR-T cell therapy is emerging from the field of hematological malignancies. Immunomodulatory approaches seem to be a new perspective in treatment of malignant mesothelioma. This chapter aims to explore possible new therapeutic approaches in mesothelioma.

show abstract

“… 20 On the other hand, MMP2 polymorphism was suggested to have a protective role in MM. 21 Furthermore, two of the investigated MMP9 single nucleotide polymorphisms (SNPs) had significant but opposing effect on time to progression (TTP) and overall survival (OS) in MM. 22 FASL-844 polymorphism could predict progression free survival (PFS) in MM patients receiving platinum based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment

Šenk

Goričar

Kovač

et al. 2019

Radiology and Oncology

Self Cite

View full text Add to dashboard Cite

Background Malignant mesothelioma (MM) is an asbestos related aggressive tumor with poor prognosis. The aim of this study was to investigate if aquaporin 1 (AQP1) genetic polymorphisms influence the risk of MM and the response to cisplatin based MM treatment. Patients and methods The case-control study included 231 patients with MM and a control group of 316 healthy blood donors. All subjects were genotyped for three AQP1polymorphisms (rs1049305, rs1476597 and rs28362731). Logistic and Cox regression were used in statistical analysis. Results AQP1 rs1049305 polymorphism was significantly associated with MM risk in dominant model adjusted for gender and age (OR = 0.60, 95% CI = 0.37–0.96, Padj = 0.033). This polymorphism was also significantly associated with cisplatin based treatment related anaemia (unadjusted: OR = 0.49, 95% CI = 0.27–0.90, P = 0.021; adjusted: for CRP: OR = 0.52, 95% CI = 0.27–0.99, P = 0.046), with leukopenia (OR = 2.09, 95% CI = 1.00–4.35, P = 0.049) in dominant model and with thrombocytopenia (OR = 3.06, 95% CI = 1.01–9.28, P = 0.048) and alopecia (OR = 2.92, 95% CI = 1.00–8.46, P = 0.049) in additive model. AQP1 rs28362731 was significantly associated with thrombocytopenia (unadjusted: OR = 3.73, 95% CI = 1.00–13.84, P = 0.049; adjusted for pain: OR = 4.63, 95% CI = 1.13–19.05, P = 0.034) in additive model. Conclusions AQP1 may play a role in the risk of MM. Furthermore, AQP1 genotype information could improve the prediction of MM patients at increased risk for cisplatin toxicity.

show abstract

Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma

Cited by 3 publications

References 15 publications

Resveratrol inhibits ACHN cells via regulation of histone acetylation

Resveratrol inhibits ACHN cells via regulation of histone acetylation

Current Mesothelioma Treatment and Future Perspectives

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment

Contact Info

Product

Resources

About